What is CTS's health score?

CTS CORP (CTS) has a TradeApes health score of 69 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CTS's estimated fair value?

Based on our 5-year discounted cash flow model, CTS CORP's estimated fair value is $38.03 per share, representing a -40.8% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is CTS undervalued or overvalued?

Our model currently rates CTS as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CTS... Refresh in a moment for the full analysis.

CTS CORP (CTS)

Technology Overvalued low healthy

$64.21

Updated: 2026-05-30

TradeApes Score

Financial Strength

85 Strong

Operating Trend

55 Mixed

Relative Value

65 Healthy

Capital Allocation

65 Healthy

Risk

80 Strong

Est. Fair Value $38.03

DCF Upside -40.8%

Sector Rank #6606 of 7709

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− High P/E — 25–45×, growth premium already priced in

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.